Cytosorbents (CTSO) Posts Earnings Results, Beats Estimates By $0.03 EPS

Cytosorbents (NASDAQ:CTSO) posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03, Fidelity Earnings reports. Cytosorbents had a negative net margin of 83.93% and a negative return on equity of 103.90%. The company had revenue of $5.19 million during the quarter, compared to analyst estimates of $6.03 million.

Shares of CTSO stock opened at $6.53 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.70 and a quick ratio of 3.52. Cytosorbents has a 12 month low of $6.35 and a 12 month high of $14.95. The stock has a market capitalization of $224.78 million, a P/E ratio of -11.66 and a beta of 1.52.

An institutional investor recently raised its position in Cytosorbents stock. Geode Capital Management LLC grew its stake in shares of Cytosorbents Corp (NASDAQ:CTSO) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 301,498 shares of the medical research company’s stock after buying an additional 16,679 shares during the period. Geode Capital Management LLC owned approximately 0.95% of Cytosorbents worth $2,436,000 as of its most recent filing with the Securities and Exchange Commission. 26.43% of the stock is currently owned by institutional investors.

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Cytosorbents in a research report on Friday, March 8th. ValuEngine raised Cytosorbents from a “hold” rating to a “buy” rating in a research report on Friday, April 26th. Finally, Maxim Group reiterated a “buy” rating and set a $18.00 price objective on shares of Cytosorbents in a research note on Friday, March 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Cytosorbents presently has a consensus rating of “Hold” and a consensus price target of $14.67.

TRADEMARK VIOLATION NOTICE: This news story was published by Rockland Register and is the property of of Rockland Register. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

Cytosorbents Company Profile

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Read More: What is the formula for the cash asset ratio?

Earnings History for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with's FREE daily email newsletter.